
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is a top biopharmaceutical company with a diverse portfolio focused on treating and preventing life-threatening infectious diseases like HIV and hepatitis B and C. With its recent acquisition of Pharmasset, Gilead has strengthened its oncology pipeline and is poised to grow its presence in the cancer market. The company's strong financials and promising pipeline make it a solid long-term investment option.
Bears say
Gilead Sciences is facing numerous challenges that are negatively impacting its outlook. The high levels of accrued government rebates and ongoing accquisitions and impairments are causing significant financial strain on the company. Additionally, the company is heavily reliant on its hepatitis and HIV portfolio, which is facing stiff competition and potential challenges in terms of intellectual property and patent protection. Gilead's recent clinical trial results have also been mixed, with one drug showing positive results while another experiencing major setbacks. This, coupled with ongoing legal risks and potential issues with patent protection, make Gilead a risky investment.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares